Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 7,70 € (+606,42 %). La mediana es de 8,36 € (+666,97 %).
| Comprar |
2 |
| Mantener |
1 |
| Vender |
1 |
Noticias Ir al feed de noticias
Tvardi presents positive phase 1 data for STAT3 inhibitor TTI-109
Tvardi reports results from a phase 1 study of TTI-109, a phosphate prodrug of TTI-101: TTI-109 converts to TTI-101 within two hours and produces similar plasma levels at molar-equivalent doses. Twenty-one days of repeated dosing showed dose-proportional pharmacokinetics and TTI-101 concentrations above the IC50 for STAT3. Pharmacodynamic data document up to a 60% reduction in STAT3-driven immune cell populations; diarrhea was shorter with TTI-109 than with TTI-101. Tvardi plans to further develop TTI-109 for dermatological and gastrointestinal indications, pending IND approval and additional funding. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | 0 | 100,00 % |
| Beneficio neto | -5,66 M | 260,03 % |
| EBITDA | -5,79 M | 261,90 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 10,48 M € |
Número de acciones | 9,38 M |
Máximo/mínimo de 52 semanas | 38,40 € - 0,82 € |
| Dividendos | No |
Beta | 0,39 |
Ratio P/E | -0,46 |
Ratio PEG | 0,01 |
Ratio P/B | 1,42 |
Ratio P/S | 0,00 |
Perfil de la empresa
| Nombre | Tvardi Therapeutics |
| CEO | Imran Alibhai |
| Empleados | 12 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | TVRD |
